Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,003 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)

NCT03188536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • H Universitario Puerta del Mar Cadiz, Andalusia, Spain
  • H Virgen de las Nieves Granada, Andalusia, Spain
  • Hospital Juan Ramon Jimenez Huelva, Andalusia, Spain
  • H Jerez Jerez de la Frontera, Andalusia, Spain
View all 30 locations
View Trial Details
Completed

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

NCT02192333

Conditions
Behavior, Behavioral Symptoms, Bone Diseases, +40 more
Locations
  • UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
View Trial Details
Completed

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

NCT02809053

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Research site Whittier, California, United States
  • Research Site Canberra, Australian Capital Territory, Australia
  • Research site Temuco, Araucania, Chile
  • Research site Hradec Králové, Czechia
View all 25 locations
View Trial Details
Completed

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia

NCT02491398

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI Ancona, Italy
  • U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno Ascoli Piceno, Italy
  • S.O.C. di Medicina Interna B - Ospedale - Cardinal Massaia di Asti Asti, Italy
  • Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi Bologna, Italy
View all 41 locations
View Trial Details
Completed

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

NCT01248923

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • Arizona Clinical Research Center, Inc. Tucson, Arizona, United States
  • City of Hope Duarte, California, United States
  • Emory University, Winship Cancer Institute Atlanta, Georgia, United States
View all 13 locations
View Trial Details
Completed

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

NCT02759016

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • City of Hope Duarte, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Oregon Health and Sciences University Portland, Oregon, United States
View Trial Details

Related conditions